New hope for Kala-Azar: experimental drug shows promise in ethiopia
NCT ID NCT05957978
First seen Jan 09, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This study tested a new drug called LXE408 for people with primary visceral leishmaniasis, a serious parasitic disease. Fifty-two adults in Ethiopia received either LXE408 or standard treatment. The main goal was to see if the drug could cure the infection by day 28, meaning symptoms improved and no parasites were found in the spleen or bone marrow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY VISCERAL LEISHMANIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Gondar
Gonder, Ethiopia
Conditions
Explore the condition pages connected to this study.